ALK and non-small cell lung carcinoma: Similarly, we reported frequencies of lymphangitic carcinomatosis of 37% in patients with ALK-rearranged NSCLC [45] and of 42% in those with ROS1-rearranged NSCLC [48], in comparison to less than 12% in our current cohort.